Speakers and delegates at the International Expert Forum: Complement Therapeutics in Clinical Practice in Kidney Disease in Singapore As complement therapeutics expand across kidney diseases, how should clinicians decide when to use them, how to monitor response, and when to change or stop treatment? From September 16-18, 113 experts from 32 countries gathered in Singapore for...
Kidney International® A single-arm phase 2 trial of an investigational RNA therapeutic targeting complement factor B (sefaxersen) for treatment of IgA nephropathy IgA nephropathy (IgAN) involves activation of the complement alternative pathway, contributing to kidney inflammation and disease progression. In this global, open-label phase 2 trial, patients with biopsy-confirmed IgAN received sefaxersen, an antisense inhibitor of complement factor B, to...
From May 2–4, 88 leading experts in nephrology gathered in Budapest, Hungary, for the “ISN’s International Expert Forum on Complement Therapeutics in C3G and IgAN” — an intensive two-day event that put the spotlight on some of the most pressing questions and promising developments in kidney care today. Through a series of in-depth presentations, international...
Watch the video for an animated explanation of the study based on the visual abstract. These resources were supported by Vera Therapeutics
The ISN has added two new webinars to its Rare Kidney Disease Toolkit, focusing on immunoglobulin A nephropathy (IgAN) and C3 glomerulopathy (C3G). These expert-led sessions offer valuable insights into diagnosing, managing, and treating these rare but challenging kidney diseases. Watch "Advancements in C3 Glomerulopathy (C3G)," featuring David Kavanagh (UK), Alison Ma (Hong Kong), and...
Join Jonathan Barratt (UK) and Richard Lafayette (US) as they explore the challenges of treating patients with IgA nephropathy (IgAN), especially younger individuals. Listen here With new medications now available, navigating treatment options has become more complex. Professor Lafayette presents a compelling case study from his practice, highlighting the real-world challenges of managing IgAN. This podcast is...
This visual abstract was supported by an unrestricted educational grant from Chinook Therapeutics, a Novartis Company.
The latest findings on the pathogenesis and treatment of IgAN will be presented and discussed at the 17th International Symposium on IgA Nephropathy in Tokyo, Japan, from September 27-30, 2023. The ISN, the Japanese Society of Nephrology (JSN), and the Asian Pacific Society of Nephrology (APSN) will hold a joint session, "International Comparison, East...
